| INTRODUCTION
Tumor markers are useful parameters to help diagnose cancer and to monitor treatment. 1 However, their clinical applications are often limited in pregnant women as a result of pregnancy-induced physiological changes. 2 Carbohydrate antigen 125 (CA125) is the most widely used tumor marker for ovarian cancer. In pregnant women, the specificity of CA125 is limited because of the marked increase, particularly during the first trimester of pregnancy. 3 In recent years, human epididymis protein 4 (HE4) has been proposed as a novel biomarker for ovarian cancer, with higher specificity and sensitivity. [4] [5] [6] It is
reported that HE4 and CA125 are complimentary. The risk of ovarian malignancy algorithm (ROMA), which is a qualitative serum test that combines the assessment of HE4 and CA125 levels with menopausal status to generate numerical score, has been shown to have the best diagnostic performance in the assessment of epithelial OC risk. 7, 8 Jie Lu and Zhipeng Zheng authors contributed equally to this article.
Numerous studies have shown that CA125 and HE4 values in pregnant women varied according to different pregnancy stages and ethnic factor. 9-11 Therefore, the currently used reference intervals (RIs)
for non-pregnant women do not appear to be available for pregnant women. For the Chinese population, it is necessary to establish accurate gestational stage-dependent RIs. However, the establishment of RIs for CA125 during pregnancy has been limited because of wider fluctuations. [12] [13] [14] [15] Previous studies have also shown that age, fertility status, menopause, and ethnicity may affect HE4 serum levels.
11, [16] [17] [18] In this state, the ROMA index may be a more ideal tumor marker for pregnant women.
To date, there are no studies on the ROMA index for pregnant women, partly because it is difficult to define menopause in the condition of pregnancy. In this study, we initially established RIs for the ROMA index during pregnancy, which were calculated using the premenopausal algorithms according to the definition reported by Moore et al 19 The aim of this study was to establish the RIs for HE4, CA125, and the ROMA index during pregnancy. Furthermore, we determined misclassification of having abnormal values of these tumor markers in this study and compared these findings to evaluate the clinical application of the RIs we established for pregnant women. 
| Laboratory methods

| ROMA index calculation
The ROMA index was calculated according to the levels of CA125
and HE4 to classify patients as being at a low or high risk for ovarian cancer. A predictive index (PI) was calculated using the following algorithms: The ROMA value (predictive value) was subsequently calculated using the following equation:
LN indicates the natural logarithm; e indicates the base of the natural logarithm.
Premenopausal and postmenopausal women with a ROMA value ≥ 11.4% and ≥29.9%, respectively, had a higher risk of ovarian cancer.
According to Moore et al women were considered to be premenopausal if they had a period within 1 year of the study blood draw.
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Therefore, the ROMA index in this study is calculated using the premenopausal algorithm.
| Statistical analysis
All statistical analyses were performed using SPSS statistical software Kruskal-Wallis H test was performed to assess the differences among trimesters. The level of statistical significance was set at P < .05.
| RESULTS
| CA125, HE4, and the ROMA index values during different trimesters of pregnancy
In this study, we measured serum HE4 and CA125 concentrations in 1006 pregnant women. The results of Kolmogorov-Smirnov test
, and ROMA (C) in healthy pregnant women during different gestational periods (*P < .05, ***P < .001, ****P < .0001) showed that HE4, CA125, and ROMA index values in our study were not in normal distribution. Therefore, we calculated the RIs with nonparametric method.
The variation trends of the CA125, HE4, and ROMA index values during pregnancy are summarized in Figure 1 . In our study, ele- to second (median 4.5%) trimester (P < .05) and from the second to third (median 9.8%) trimester (P < .0001). Overviews of the CA125
and HE4 values during pregnancy are shown in Tables 1 and 2 . We summarized the CA125 values in 5studies from different countries.
Elevated CA125 levels in the first trimester were identified in all studies. 15, [20] [21] [22] [23] One study identified elevated CA125 levels in the second trimester, 23 and 2 studies identified elevated levels in the third trimester. 15, 23 These levels were lower than those reported herein during each trimester. For HE4, Moore et al reported that the median concentrations of HE4 were not significantly different among trimesters; however, these concentrations were significantly lower than their premenopausal counterparts. 11 The concentrations reported in our study were higher than those of Moore et al in the second and third trimesters. 
| RIs for pregnant women
In this study, the most obvious variations were identified in the RIs for CA125 during pregnancy ( Table 3 ). The cutoff values for CA125 in the first (309.5 U/mL) and third (113.3 U/mL) trimesters were substantially higher than the cutoff value for non-pregnant women (35 U/mL).
In contrast, the cutoff values for HE4 in each of the 3 trimesters were lower than the cutoff value of 140 pmol/L. The cutoff values for the ROMA index in the first (8.7%) and second (10.0%) trimesters were close to the cutoff value of 11.4%.
| Comparisons of RIs for the ROMA index, CA125, and HE4
For the ROMA index, only 2% of participants were misclassified as out of the normal range in the first 2 trimesters. For HE4, the RI for
Chinese premenopausal women (<65.8 pmol/L) was more suitable for evaluation of HE4 levels in pregnant women because of the relationship between increasing serum levels of HE4 and increasing age.
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Approximately 0.3%, 1.1%, and 24.9% of pregnant women were misclassified as being out of normal range in the first, second, and third trimesters, respectively.
Using the cutoff value for non-pregnant women (35 U/mL), approximately 216 (70.6%), 14 (4%), and 150 (42.9%) pregnant women had CA125 values that were misclassified as out of the normal range in the first, second, and third trimesters, respectively. We analyzed the participants who were misclassified as having abnormal CA125 values. Among these participants, only 0.9%, 0%, and 40% of the pregnant women had ROMA index values that were above the cutoff value of 11.4%, and 0.5%, 0%, and 23.3% had HE4 values that were above the cutoff value of 65.8 pmol/L in the first, second, and third trimesters, respectively. In the participants who had CA125 values that were above the cutoff values for pregnant women established in this study, only 0%, 0%, and 47% of pregnant women had HE4 and ROMA index beyond the normal range (Table 4) .
| DISCUSSION
In this study, clear variations in HE4, CA125, and the ROMA index the second and third trimesters. 23 Ercan et al identified elevated CA125 levels in the third trimester. 15 Our results showed higher CA125 levels than those reported previously, particularly in the first and third trimesters, with wider fluctuations. These differences may be caused by the different methods and study populations. Therefore, we recommend appropriate RIs for CA125 for the pregnant women in China.
According to our results, the RI for non-pregnant women (<35 U/ mL) was only suitable for pregnant women in the second trimester. The RIs for HE4 established in this study were approximately 2.0-
